Chemotherapeutic agents of various mechanisms of action, such as bortezomib, doxorubicin and panobinostat were selected to sensitize TRAIL-resistant lung adenocarcinoma cells A549 and HT-29 colorectal adenocarcinoma to TRAIL or the DR5 selective TRAIL variant DR5-B. Here, TNFRSF10B is linked to lung adenocarcinoma.